Subscribe

Endometrial Cancer

GOG-LAP2: Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer

Laparoscopic surgical staging for uterine cancer is feasible and safe, showing fewer complications and shorter hospital stays compared to laparotomy

GOG 261: Carboplatin-Paclitaxel Versus Ifosfamide-Paclitaxel in Carcinosarcoma

Carboplatin/Taxol is not inferior to Ifos/Taxol in terms of OS and significantly increases PFS, making it a new standard treatment for carcinosarcoma

GOG 249: Vaginal Brachytherapy Plus Chemotherapy vs Pelvic Radiation in High-Risk Early-Stage Endometrial Cancer

The study did not demonstrate superiority or equivalence due to similar outcomes in both arms. The higher incidence of pelvic/para-aortic nodal failures in the VCB/C arm suggests the importance of pelvic RT in preventing regional recurrences.

KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Lenvatinib plus pembrolizumab significantly improves progression-free and overall survival compared to chemotherapy among patients with advanced endometrial cancer.

GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer

The TC regimen demonstrated noninferiority to TAP in terms of OS and PFS while offering a better toxicity profile, making it a suitable first-line treatment for advanced endometrial cancer

GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

PORTEC-3: Adjuvant Chemoradiotherapy vs. Radiotherapy Alone for High-Risk Endometrial Cancer (Final Results)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

NRG-GY012: Olaparib, Cediranib, and Olaparib+Cediranib vs. Cediranib in Recurrent Endometrial Cancer

NRG-GY012

RUBY: Dostarlimab plus Chemotherapy for Primary Advanced or Recurrent Endometrial Cancer

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

NRG GY018: Pembrolizumab in Advanced Endometrial Cancer

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer